Abstract O10 Figure 1

compared to a strategy based on symptoms alone. The aim of this study was to determine whether normalisation of FC (<250 µg/g) within 12-months of diagnosis is associated with a reduction in disease progression in CD.

Methods This was a retrospective cohort study performed at a tertiary IBD centre. All incident cases of CD diagnosed between 2005–2017 were identified. Patients with a FC measurement of >250 µg/g at diagnosis who also had at least 1 follow up FC measured within the first 12-months of diagnosis and >12 months of follow up were included. The primary endpoint was a composite of progression in Montreal disease behaviour (B1 to B2/3 or B2 to B3 or new perianal disease), surgery or hospitalisation.

Results A total of 375 patients were included with a median follow up of 5.3 years (IQR 3.1–7.4). Normalisation of FC (<250 µg/g) within 12 months of diagnosis was confirmed in 43.5% (n=163/375) of the cohort. On multivariable Cox-proportional hazards regression analysis, individuals who normalised their FC within 12 months of diagnosis had a significantly lower risk of composite disease progression (HR 0.351, 95% CI 0.235–0.523, p<0.001) (figure 1). In addition, normalisation of FC was the only predictor that remained significant for all of the separate progression end-points (progression in Montreal behaviour/new perianal disease: HR 0.250, 95% CI 0.122–0.512, p<0.001; hospitalisation: HR 0.346, 95% CI 0.217–0.553, p<0.001; surgery: HR 0.370. 95% CI 0.181–0.755, p=0.006). Patients initiated on a biologic within 3 months of diagnosis were significantly more likely to normalise their FC within 12 months of diagnosis (OR 4.288, 95% CI 1.585–11.0601, p=0.004).

Conclusions Normalisation of FC by 12-months of diagnosis is associated with a reduced risk of disease progression in CD. The immediate implication for healthcare providers and patients is that by ensuring resolution of mucosal inflammation - using FC as a proxy target - within 1 year of diagnosis has a dramatic effect on disease course.

O11   **OUTCOMES OF GP OUTREACH PROGRAMME OFFERING COLONOSCOPIC SURVEILLANCE FOR IBD PATIENTS MANAGED IN PRIMARY CARE**

Halina Windak, Vida Cairnes*, Neil Chanchlani, Desmond Chee, Benjamin Hamilton, Neel Heerasing, Peter Hendy, Simeng Lin, Nicholas Kennedy, James Goodhand, Tariq Ahmad, Claire Gordon. *Royal Devon and Exeter Nhs Foundation Trust, Exeter, UK*

Introduction Colonoscopic surveillance in IBD patients can reduce the development of colorectal cancer (CRC) and the rate of CRC-associated death. We recently reported that 27% of IBD patients living in East Devon are managed exclusively in primary care of whom about 23% maybe eligible for colonoscopic surveillance. We devised an outreach programme, whereby we invited primary care physicians to enrol these patients in a colonoscopic surveillance programme.

Methods In December 2017 we contacted 37 general practices, where 161 patients with UC who were eligible for surveillance had been identified. Each practice was sent a letter explaining the goals of the project, a link to the National Institute for Healthcare and Clinical Excellence (NICE) guidance for CRC surveillance in IBD patients and patient information booklets. We informed the practices of their eligible patients and asked them to refer patients for secondary care IBD consults if appropriate. We included an outcome form that captured whether the patient was referred, was deemed inappropriate for surveillance, had surveillance elsewhere, had declined surveillance, or was no longer registered at the practice.

Results Sixty-five percent of practices (24/37) responded and we received responses for 57 of 161 (35%) potentially eligible patients. Thirty-five (61%) patients were referred to our IBD service; 7 (12%) patients declined surveillance; 7 (12%) patients were deemed by their GP to be unfit for surveillance and 5 (10%) were no longer registered at the identified GP practice; 2 (4%) had surveillance arranged elsewhere and 1 (2%) patient had died. Amongst the 35 patients referred to secondary care; 22 (63%) underwent surveillance colonoscopy, 12 (34%) declined surveillance after discussion or did not attend their booked appointments and one is awaiting colonoscopy. Half of patients who had a colonoscopy had active inflammation. We diagnosed one CRC He was an elderly man with a locally invasive signet ring caecal tumour, without distant metastases, who went onto to have a curative right hemicolectomy without complication.

Conclusions Patients with longstanding IBD are frequently managed exclusively in primary care and maybe overlooked for colonoscopic CRC surveillance. There is a need to implement processes to facilitate identification and recall of patients eligible for surveillance across primary and secondary care.

O12   **REVERSION TO BASELINE MICROBIOME FOLLOWING SUCCESSFUL COURSE OF EXCLUSIVE ENTERAL NUTRITION IN PAEDIATRIC CROHN'S DISEASE**

[1]Michael Logan*, [1]Clare M Clark, [1]Ben Nichols, [2]Umer Zeeshan Ijaz, [3]Simon Milling, [4]Richard Hansen, [4]Richard K Russell, [1]Konstantinos Gerasimidis. [1]*Human Nutrition, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK*; [2]*Civil Engineering, School of Engineering, University of Glasgow, Glasgow, UK*; [3]*Institute for Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK*; [4]*Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK*

Introduction To characterise the microbiome composition and functionality in paediatric Crohn's disease (CD) patients during a course of exclusive enteral nutrition (EEN) and subsequent food-reintroduction

Methods CD patients were recruited between August 2014-June 2016. Patients were treated with an 8 wk course of EEN. Clinical disease activity was defined using the weighted paediatric Crohn's disease activity index (wPCDAI). Serial faecal samples were collected prior to EEN, at 30d and 56d of EEN, and two further samples were collected post-EEN (17d